Navigation Links
King Pharmaceuticals To Acquire Alpharma for Approximately $1.6 Billion
Date:11/24/2008

tendered and not withdrawn pursuant to the tender offer.

"We are excited about the combination of King and Alpharma, which will create a leading specialty pharmaceutical company with greater scale and capabilities," stated Brian A. Markison, Chairman, President and Chief Executive Officer of King. "Together, we will be better positioned to deliver superior value to our stockholders and significant benefits to employees of both companies. In addition, the transaction will create a stronger platform to deliver innovation to our customers. King and Alpharma are highly complementary and we look forward to even greater success as a combined company."

"The transformation of Alpharma over the past two years has created tremendous shareholder value, and we have consistently said that we will act in the best interest of shareholders," commented Dean Mitchell, Alpharma's President and Chief Executive Officer. "Therefore, after careful evaluation, our Board determined that a combination with King is in the best interest of our shareholders and provides them immediate access to this value. We believe the combined company has a compelling strategic logic and will create a strong company for both shareholders and employees. We look forward to working with King's team to integrate our companies."

King noted that Alpharma's Animal Health division will increase the diversification of King's business and is expected to provide steady cash flow to fuel future strategic initiatives, much like its Meridian auto-injector franchise. Additionally, King believes the strong commercialization capabilities that this combination provides will enhance the anticipated launches of REMOXY(R) (long-acting oral oxycodone) and EMBEDA(TM) (morphine sulfate extended-release with sequestered naltrexone hydrochloride), both of which are designed to resist or deter common methods of opioid misuse and abuse. Commercialization of these produc
'/>"/>

SOURCE King Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine news :

1. Transdel Pharmaceuticals Appoints Mr. Lynn Swann, Pro-Football Hall of Famer, ABC Sports Broadcaster, and Former Chairman of the Presidents Council on Physical Fitness and Sports, to Board of Directors
2. Data Published in Nature Medicine Highlights Ability of Peregrine Pharmaceuticals Bavituximab to Cure Lethal Virus Infections
3. Alseres Pharmaceuticals, Inc. Announces $1 Million Financing
4. Keryx Biopharmaceuticals Receives Nasdaq Notification
5. Purdue Pharma L.P. Announces a Global Strategic Alliance With Infinity Pharmaceuticals to Advance Discovery and Development Programs in Oncology and Neuropathic Pain
6. FDA Accepts Vanda Pharmaceuticals Iloperidone Resubmission and Sets New Action Date
7. Amylin Pharmaceuticals to Present at Lazard Capital Markets Healthcare Conference
8. MiddleBrook Pharmaceuticals Reports Third Quarter 2008 Financial Results
9. MAP Pharmaceuticals Reports Third Quarter of 2008 Financial Results
10. Ferring Pharmaceuticals Promotes William Garbarini to Vice President of New Orthopaedics and Urology Business Unit
11. Alexza Pharmaceuticals Announces Upcoming Conference Participation and Webcasts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... 28, 2015 Orem, UT—Dymicron, Inc., (dymicron.com) ... using their unique Triadyme-C cervical total disc replacement device. ... William D. Smith at the American Institute of Minimally ... are responding well to the implantation of the Dymicron ... Spine Center and Chief of Neurosurgery for the University ...
(Date:5/28/2015)... Omaha, NE (PRWEB) May 28, 2015 ... healthcare staffing, including nurse practitioner jobs, has announced that ... Association of Nurse Practitioners’ 2015 National Conference to be ... , AANP offers educational programming, networking opportunities, and ... Aureus Medical’s Advanced Practice division will be ...
(Date:5/28/2015)... 2015 Peggy J. Lynam, PT, DPT, NCS ... American Physical Therapy Association House of Delegates for the New ... Delegate Assembly. This will be her second term. ... coordinator and principle spokesperson for the Chapter delegation and presides ... or Delegate Assembly may direct the Chief Delegate to present ...
(Date:5/27/2015)... Gravity and volume loss in the skin have ... Holly CaSaroll, is excited to introduce a custom menu ... face, without surgical intervention, and without downtime. , “We ... approved procedure that can lift skin using focused ultrasound, ... new more lifting formula than its predecessor Radiesse, to ...
(Date:5/27/2015)... Thermage was the first to come out with ... 2007 coinciding with the release of NXT or CPT, the ... Aesthetics was the first practice in New York to debut ... results that had never been achieved before non-surgically. Even ... considered by many as the leading skin tightening device. ...
Breaking Medicine News(10 mins):Health News:Dymicron, Inc., Announces the First Human Implantation of their Triadyme-CTM Cervical Total Disc Replacement Device in Cyprus 2Health News:Healthcare Staffing Leader, Aureus Medical Group, to Exhibit at the American Association of Nurse Practitioners’ 2015 National Conference 2Health News:Skin Expert Holly CaSaroll Announces New Cutting Edge Results with RadiessePlus Filler Available at Detroit Skin and Wellness Clinic 2Health News:Non-Surgical Fat Reduction and Skin Tightening Procedures, Thermage and Exilis, Increase 200% at Precision Aesthetics in New York, April 2015 2
... hospital ranked as one of Americas Best by U.S. News ... days than those admitted to a non-ranked hospital , according ... of Internal Medicine, one of the JAMA/Archives journals. ... mortality measures that are publicly reported by the Centers for ...
... eating uncooked fish dishes like koi-pla puts people in ... cause a type of liver cancer called cholangiocarcinoma ... weeks PLoS Medicine. ,Banchob Sripa (Khon Kaen ... food-borne trematode Opisthorchis viverrini (the SE Asian liver fluke) ...
... research, published in the July issue of the journal ... method for enhancing the potency and effectiveness of ... a variety of human cancers. , A ... human cancer cells to a promising treatment currently being ...
... According to a study published in the July 10, ... American Academy of Neurology , People with early Parkinsons ... of hallucinations, sleepiness, and swelling. ,By identifying ... for early intervention and possibly reduce disability, said study ...
... fashion designer Giorgio Armani's group said Wednesday it will open ... of both hot springs and high fashion. ... Ginza, one of Tokyo's ritziest districts, as part of its ... market. ,The 6,000 square-meter (65,000 square-foot) complex opening ...
... of British scientists claims they can soon release the worlds ... so, the NHS Trust of UK will stand to save billions ... most common neurological diseases in the western world, costs the NHS ... scientists, they have identified a series of proteins, which are most ...
Cached Medicine News:Health News:Americas Best Hospital Reduced Heart Attack Rates 2Health News:Americas Best Hospital Reduced Heart Attack Rates 3Health News:New Cancer Therapy in Clinical Trial 2Health News:Early Parkinsons Show Hallucination,sleepiness 2Health News:Simple Blood Test May Predict Alzheimers Disease 2
(Date:5/27/2015)... , May 27, 2015 PharmaPoint: Type 1 Diabetes ... Summary Type 1 diabetes (T1D) is an autoimmune disease ... means that the body can no longer produce insulin. Over ... as at present, no other treatment can be offered to ... of insulin analogs with different times of action - long-acting ...
(Date:5/27/2015)... 27, 2015  Precision Advisors ( www.precisionadvisors.com ), a ... 2015 Digital Trends Study of 145 managed care executives. ... the concepts of big data and predictive analytics, but ... The Health Information Technology for Economic and Clinical ... make use of electronic medical records (EMRs) by 2014. ...
(Date:5/27/2015)... -- LumiThera Inc., a developmental stage medical device company ... disorders and disease, announced today that they were ... Life Sciences Discovery Fund (LSDF) commercialization grant. LumiThera was ... grants worth $500,000 to provide for commercialization activities ... macular degeneration (AMD). LSDF executive ...
Breaking Medicine Technology:PharmaPoint: Type 1 Diabetes - Global Drug Forecast and Market Analysis to 2023 2PharmaPoint: Type 1 Diabetes - Global Drug Forecast and Market Analysis to 2023 3PharmaPoint: Type 1 Diabetes - Global Drug Forecast and Market Analysis to 2023 4Precision Advisors Digital Trends Study: Less Than Half of Managed Care Organizations Have Access to Electronic Medical Records Data 2Precision Advisors Digital Trends Study: Less Than Half of Managed Care Organizations Have Access to Electronic Medical Records Data 3LumiThera Receives LSDF Commercialization Grant Award 2
... TUSTIN, Calif., Dec. 5, 2011  Radient Pharmaceuticals Corporation ... In Vitro Diagnostic (IVD) cancer test, ... to the 2012 Gastrointestinal Cancers Symposium (ASCO Conference) ... submitted. The meeting will be held on January ...
... ANGELES, December 2, 2011  WestPark Capital, Inc. announced the ... Amex: ISR). A total of 2,817,988 shares of common stock ... common stock were sold, generating gross proceeds of $2,592,549 ... to fund new applications for IsoRay,s Cesium-131 technology to ...
Cached Medicine Technology:Radient Pharmaceuticals' Two Abstracts Submitted to 2012 Gastrointestinal Cancers Symposium (ASCO) Regarding Onko-Sure® Utility in Colorectal Cancer Are Accepted for Presentation 2Radient Pharmaceuticals' Two Abstracts Submitted to 2012 Gastrointestinal Cancers Symposium (ASCO) Regarding Onko-Sure® Utility in Colorectal Cancer Are Accepted for Presentation 3WestPark Capital, Inc. Announces $2.6 Million IsoRay Offering 2
... Ultra thin collagen coated highly ... ultra thin wall construction offers ... The Hemacarotid UltraThin Patch provides ... conformability, and healing, without suture ...
The VasoSeal Low Profile device is designed for smaller sheath angiography procedures. VasoSeal Low Profile. Seal your arterial punctures with confidence....
D-Stat Radial is a dry version of the D-Stat together with a compression band, and is designed for the control of surface bleeding from vascular access sites, including the sites on the radial artery...
... EVS is engineered to close arteriotomies ... ergonomic stapler with a simple trigger ... A deliver sheath gently locks ... control of the site before, during, ...
Medicine Products: